# FDA 483 - Richy Agajanian, M.D. - March 07, 2019

Source: https://www.keypedia.com/records/483/richy-agajanian-md/5617656d-f03d-464a-8819-ccae493d701b

> FDA 483 for Richy Agajanian, M.D. on March 07, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Richy Agajanian, M.D.
- Inspection Date: 2019-03-07
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Richy Agajanian, M.D. in Whittier, CA, a clinical investigator, revealed a significant issue regarding the conduct of an investigation. The firm failed to adhere to the signed statement of investigator and investigational plan, specifically concerning the reporting of adverse events and the review and maintenance of subject diaries. This indicates a failure to follow study protocols for clinical trials.

## Related Officers

- [Bioresearch Monitoring Specialis](https://www.keypedia.com/people/denise-l-burosh/075a442f-67e0-4a65-9c09-e8819a329773)

Company: https://www.keypedia.com/companies/richy-agajanian-md/7a995b52-aa45-4041-9940-ed65629ade65

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6